Literature DB >> 22984635

Drug Repurposing for Cancer Therapy.

Carlos M Telleria1.   

Abstract

Entities:  

Year:  2012        PMID： 22984635      PMCID： PMC3440183          DOI： 10.4172/1948-5956.1000e108

Source DB:  PubMed          Journal:  J Cancer Sci Ther


× No keyword cloud information.
  35 in total

Review 1.  The evolution of thalidomide and its IMiD derivatives as anticancer agents.

Authors:  J Blake Bartlett; Keith Dredge; Angus G Dalgleish
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

2.  Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I.

Authors:  David W Carley
Journal:  IDrugs       Date:  2005-04

3.  The successful regression of large solid sarcoma 180 tumors by platinum compounds.

Authors:  B Rosenberg; L VanCamp
Journal:  Cancer Res       Date:  1970-06       Impact factor: 12.701

4.  The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes.

Authors:  B Rosenberg; L Van Camp; E B Grimley; A J Thomson
Journal:  J Biol Chem       Date:  1967-03-25       Impact factor: 5.157

Review 5.  Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.

Authors:  E Nadal; E Olavarria
Journal:  Int J Clin Pract       Date:  2004-05       Impact factor: 2.503

Review 6.  Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects.

Authors:  Jürgen Knobloch; Ulrich Rüther
Journal:  Cell Cycle       Date:  2008-02-14       Impact factor: 4.534

7.  Control of birth in rats by RU 486, an antiprogesterone compound.

Authors:  M J Bosc; G Germain; A Nicolle; M Mouren; D Philibert; E E Baulieu
Journal:  J Reprod Fertil       Date:  1987-01

Review 8.  Thalidomide for treatment of multiple myeloma: 10 years later.

Authors:  Antonio Palumbo; Thierry Facon; Pieter Sonneveld; Joan Bladè; Massimo Offidani; Francesca Gay; Philippe Moreau; Anders Waage; Andrew Spencer; Heinz Ludwig; Mario Boccadoro; Jean-Luc Harousseau
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

9.  Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.

Authors:  Alicia A Goyeneche; Erin E Seidel; Carlos M Telleria
Journal:  Invest New Drugs       Date:  2011-03-22       Impact factor: 3.850

10.  Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004.

Authors:  M Vessey; R Painter
Journal:  Br J Cancer       Date:  2006-07-04       Impact factor: 7.640
View more
  10 in total

1.  Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.

Authors:  Carlos D Gamarra-Luques; Maria B Hapon; Alicia A Goyeneche; Carlos M Telleria
Journal:  J Ovarian Res       Date:  2014-04-27       Impact factor: 4.234

Review 2.  Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics.

Authors:  J Javier Hernandez; Michael Pryszlak; Lindsay Smith; Connor Yanchus; Naheed Kurji; Vijay M Shahani; Steven V Molinski
Journal:  Front Oncol       Date:  2017-11-14       Impact factor: 6.244

3.  Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.

Authors:  Zuzana Mrkvová; Stjepan Uldrijan; Antonio Pombinho; Petr Bartůněk; Iva Slaninová
Journal:  Molecules       Date:  2019-06-07       Impact factor: 4.411

4.  The effects of growth hormone on therapy resistance in cancer.

Authors:  Reetobrata Basu; John J Kopchick
Journal:  Cancer Drug Resist       Date:  2019-09-19

5.  Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.

Authors:  Sundee Dees; Laura Pontiggia; Jean-Francois Jasmin; Isabelle Mercier
Journal:  Cancer Biol Ther       Date:  2020-03-13       Impact factor: 4.742

6.  Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy.

Authors:  Kavita Gaur; Alexandra M Vázquez-Salgado; Geraldo Duran-Camacho; Irivette Dominguez-Martinez; Josué A Benjamín-Rivera; Lauren Fernández-Vega; Lesly Carmona Sarabia; Angelys Cruz García; Felipe Pérez-Deliz; José A Méndez Román; Melissa Vega-Cartagena; Sergio A Loza-Rosas; Xaymara Rodriguez Acevedo; Arthur D Tinoco
Journal:  Inorganics (Basel)       Date:  2018-11-30

7.  Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.

Authors:  Rajith K R Rajoli; Henry Pertinez; Usman Arshad; Helen Box; Lee Tatham; Paul Curley; Megan Neary; Joanne Sharp; Neill J Liptrott; Anthony Valentijn; Christopher David; Steven P Rannard; Ghaith Aljayyoussi; Shaun H Pennington; Andrew Hill; Marta Boffito; Steve A Ward; Saye H Khoo; Patrick G Bray; Paul M O'Neill; W David Hong; Giancarlo A Biagini; Andrew Owen
Journal:  Br J Clin Pharmacol       Date:  2020-12-01       Impact factor: 4.335

8.  Evaluating Ligand Modifications of the Titanocene and Auranofin Moieties for the Development of More Potent Anticancer Drugs.

Authors:  Lauren Fernandez-Vega; Valeria A Ruiz Silva; Tania M Domínguez-González; Sebastián Claudio-Betancourt; Rafael E Toro-Maldonado; Luisa C Capre Maso; Karina Sanabria Ortiz; Jean A Pérez-Verdejo; Janeishly Román González; Grecia T Rosado-Fraticelli; Fabiola Pagán Meléndez; Fabiola M Betancourt Santiago; Daniel A Rivera-Rivera; Carlos Martínez Navarro; Andrea C Bruno Chardón; Axel O Vera; Arthur D Tinoco
Journal:  Inorganics (Basel)       Date:  2020-01-26

Review 9.  Systemic therapy of Cushing's syndrome.

Authors:  Niels Eckstein; Bodo Haas; Moritz David Sebastian Hass; Vladlena Pfeifer
Journal:  Orphanet J Rare Dis       Date:  2014-08-05       Impact factor: 4.123

10.  A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening.

Authors:  Jouhyun Jeon; Satra Nim; Joan Teyra; Alessandro Datti; Jeffrey L Wrana; Sachdev S Sidhu; Jason Moffat; Philip M Kim
Journal:  Genome Med       Date:  2014-07-30       Impact factor: 11.117
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.